Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a vaccine protect spleen injury patients from deadly infections?

NCT ID NCT02232191

Recruiting now Disease control Sponsor: University of California, Davis Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

People without a working spleen are at high risk of severe infections from pneumococcus bacteria. This study looks at how well the pneumococcal vaccine works in adults aged 18-65 who have a spleen injury and are treated with monitoring, embolization, or spleen removal. Researchers will measure antibody levels to see which treatment approach leads to the best immune response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Pneumovax-23 (pneumococcal polysaccharide vaccine)
What this could lead to
If successful, this could help doctors choose the best treatment for spleen injuries to maximize vaccine protection against serious infections.
What could go wrong
This is a small Phase 2 study with only 75 participants, so results may not apply to everyone. The vaccine may not provide full protection, and individual responses can vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASPLENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

familial isolated congenital asplenia pneumococcal infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASPLENIA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of California, Davis Medical Center

    RECRUITING

    Sacramento, California, 95817, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.